Bridging Continents: Navigating U.S. Funding for Swiss Biotechs
Panel discussion summary
This panel brings together key stakeholders from both sides of the Atlantic to explore the opportunities and challenges of securing U.S. funding for Swiss biotech companies. Investors and representatives from Swiss biotechs will share their insights on the current landscape, discuss strategies for successful fundraising, and highlight the unique advantages and potential hurdles faced by Swiss firms in the U.S. market.
Date, time and room information
May 6, 16:00-16:45, room Marriott 3+4+5
Moderation
| Name | Position | Institution |
|---|---|---|
| Branden C. Berns | Partner | Gibson, Dunn & Crutcher LLP |
Panelists
| Name | Position | Institution |
|---|---|---|
| Matthias Bodenstedt | CFO | MoonLake Immunotherapeutics |
| Nicolas Mosimann | Partner | Kellerhals Carrard |
| Melanie Rolli | Group CEO | Helsinn |
| Nate Chang | Operating Partner Life Sciences | Playground Global |
Kellerhals Carrard
Kellerhals Carrard's highly specialized and interdisciplinary Life Sciences team is one of the strongest in Switzerland. We advise biotech and pharma clients of all sizes from startups to large multinationals on their most prominent and complex matters, both in Switzerland and abroad.
